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Aim: Particle Replication in Nonwetting Templates (PRINT®) PLGA nanoparticles 
of docetaxel and acid-labile C2-dimethyl-Si-Docetaxel were evaluated with small 
molecule docetaxel as treatments for non-small-cell lung cancer brain metastases. 
Materials & methods: Pharmacokinetics, survival, tumor growth and mice weight 
change were efficacy measures against intracranial A549 tumors in nude mice. 
Treatments were administered by intravenous injection. Results: Intracranial tumor 
concentrations of PRINT-docetaxel and PRINT-C2-docetaxel were 13- and sevenfold 
greater, respectively, than SM-docetaxel. C2-docetaxel conversion to docetaxel was 
threefold higher in intracranial tumor as compared with nontumor tissues. PRINT-C2-
docetaxel increased median survival by 35% with less toxicity as compared with other 
treatments. Conclusion: The decreased toxicity of the PRINT-C2-docetaxel improved 
treatment efficacy against non-small-cell lung cancer brain metastasis.
First draft submitted: 6 April 2016; Accepted for publication: 8 June 2016; Published 
online: 26 July 2016
Keywords:  acid-labile docetaxel prodrug • blood–brain barrier • Particle Replication in 
 Non-wetting Templates (PRINT)® PLGA nanoparticle
Lung cancer, 80% comprised of non-small-
cell lung cancer (NSCLC), is one of the 
leading causes of cancer worldwide and the 
USA [1–3]. Lung cancer is the most com-
mon primary tumor responsible for brain 
metastases [19]. Among those diagnosed with 
NSCLC, 20–50% of patients will develop 
metastatic brain disease [2], 10% with brain 
metastases at initial diagnosis [4] and another 
30% later in their disease course following 
standard therapies.
Despite multimodality therapy with com-
binations of surgery, radiation therapy and 
chemotherapy, median survival remains less 
than one year for NSCLC brain metastatic 
patients [1,2]. NSCLC brain metastases are 
generally nonresponsive to first-line, single 
agent platinum-based chemotherapy [2,5]. 
Docetaxel (Taxotere®) is a standard second 
line systemic chemotherapy for NSCLC 
brain metastases [2].
As brain metastasis recurrence is com-
mon among patients with advanced NSCLC, 
optimizing the passage of anticancer agents 
across the blood–brain barrier, increasing 
chemotherapeutic concentrations in intracra-
nial and extracranial tumors and decreasing 
systemic toxicities are important consider-
ations to improve treatment of this disease. 
Newer delivery techniques, like nanoparti-
cles and carrier-mediated technologies, have 
illustrated these advantages in the setting of 
intracranial cancer [6–10]. Clinically, activ-
ity of nanoparticle-based systemic therapy 
has been illustrated in the setting of breast 
cancer brain metastases, another solid tumor 
type where brain metastasis recurrence is 
common [11].
While several studies have shown the supe-
riority of nanoparticle anticancer agents in 
intracranial malignancies over standard for-
mulations, the mechanism underlying this 
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observation has yet to be fully elucidated [6–12]. The 
working hypothesis has been that prolonged exposure 
to anticancer agents afforded by nanoparticle technol-
ogy may increase passage of small molecules across the 
‘blood tumor barrier,’ a barrier potentially  compromised 
by the presence of tumor [12].
Particle Replication in Nonwetting 
Templates (PRINT)® of poly-(lactic acid-co-
glycolic acid)-docetaxel
PRINT-poly(lactic acid-co-glycolic acid) (PLGA) 
nanoparticle formulations of docetaxel have shown 
superior pharmacokinetic and efficacy profiles over that 
of standard small molecule docetaxel (SM-docetaxel) 
in an extracranial NSCLC xenograft model [13]. Given 
the superior intracranial pharmacokinetic and efficacy 
profiles for nanoparticle anticancer agents in solid 
tumors, and the activity of docetaxel in NSCLC, we 
hypothesized that PRINT PLGA-docetaxel formula-
tions would increase docetaxel concentrations in intra-
cranial tumors and decrease intracranial tumor growth 
as compared with SM-docetaxel, thereby improving 
survival. We expected that the acid labile C2-prodrug 
PRINT® PLGA formulation (PRINT-C2-docetaxel), 
which should be specifically activated by an acidic 
tumor microenvironment, would increase efficacy 
with decreased toxicity over PRINT-PLGA docetaxel 
(PRINT-docetaxel).
Methods & materials
Pharmacologic agents
Small molecule docetaxel (SM-docetaxel; Taxotere) 
was obtained from the University of North Carolina 
Hospitals Pharmacy. A single step reaction of docetaxel 
with chlorodimethylethylsilane was performed to gen-
erate the C2′ alcohol of taxane, the silyl ether docetaxel 
prodrug C2, as previously described [13]. PRINT-C2-
docetaxel and PRINT-docetaxel nanoparticles were 
fabricated as previously described, to form the same 
sized cylindrical particles of PLGA polymer with a 
diameter of 80 nm and height of 320 nm, with simi-
lar drug loading [13,15–18]. Briefly, a thin film of PLGA 
and Docetaxel or C2-Docetaxel was deposited on a 6″ 
× 12″ sheet of PET (poly[ethylene terephthalate]) by 
spreading 150 μl of a 10 mg/ml PLGA and 10 mg/ml 
docetaxel or C2-docetaxel chloroform solution using 
a # 5 Mayer Rod (R.D. Specialties). The solvent was 
evaporated with heat. The PET sheet with the film 
was then placed in contact with the patterned side of 
a mold and passed through heated nips (ChemInstru-
ments Hot Roll Laminator) at 130°C and 80 psi. The 
mold was split from the PET sheet as they both passed 
through the hot laminator. The patterned side of the 
mold was then placed in contact with a sheet of PET 
coated with 2000 g/mol PVOH (poly[vinyl alcohol]). 
This was then passed through the hot laminator to 
transfer the particles from the mold to the PET sheet. 
The mold was then peeled from the PET sheet. The 
particles were removed by passing the PVOH coated 
PET sheet through motorized rollers and applying 
water to dissolve the PVOH to release the particles. 
To remove excess PVOH, the particles were purified 
and then concentrated by tangential flow filtration 
( Spectrum Labs).
A549 intracranial xenograft studies
All animal studies protocols were approved by the 
University of North Carolina, Chapel Hill Institu-
tional Animal Care and Use Committee, executed 
by the UNC Animal Studies Core, and performed 
as previously described [6,13,14]. Briefly, A549-luc-c8, 
acquired from Caliper Life Sciences (P/N 119266, 
Perkin Elmer), was propagated in culture in DMEM 
10% FBS supplemented with G418 (200 μg/ml). For 
intracranial injections, cells were harvested in log-
phase growth and suspended with 5% methylcellu-
lose in culture media. Eight to ten week Foxn1 nu/nu 
mice (UNC Animal Studies Core) were implanted 
with 200,000 cells/5 uls of cell suspension through 
stereotactic intracranial injection in the right striatum. 
Animal weights were collected from injection to sacri-
fice three-times weekly. To determine tumor volumes, 
mice were anesthetized, injected intraperitoneally with 
D-Luciferin dissolved in PBS (150 mg/kg; Caliper Life 
Sciences, MA, USA), then imaged by IVIS Lumina 
camera (Caliper Life Sciences). Images were analyzed 
with Living Image 4.0 software (Caliper Life Sciences). 
All values were corrected for background and recorded 
as photons/second.
For pharmacokinetic studies, tumors were grown 
to greater than 2 mm in diameter correlating with 
bioluminescence signal which occurred between 30 
and 40 days post-intracranial injection of tumor cells. 
The following treatments were given once by IV a) 
SM-docetaxel at 15 mg/kg, b) PRINT-docetaxel at 
30 mg/kg, c) PRINT® C2- docetaxel at 30 mg/kg. 
These doses were in SM-docetaxel equivalents and 
below previously determined maximum tolerated doses 
for nontumor bearing nude mice (nu/nu) [13]. Tumors 
were collected at n = 3 per time point per treatment, as 
shown in Figure 1. PBS controls (n = 2) were collected as 
negative controls for pharmacokinetic analysis.  Figures 
were generated using GraphPad Prism 6.
For efficacy studies, mice were grouped between 21 
and 28 days post-injection of tumor cells by intracranial 
bioluminescence signals, (nu/nu) [13]. Tumor growth by 
bioluminescence was monitored weekly. Mice weights 
were collected three-times a week throughout efficacy 
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Figure 1. Individual and mean concentrations of docetaxel and C2-docetaxel after administration of SM-docetaxel at 15 mg/
kg, PRINT-docetaxel at 30 mg/kg, or PRINT-C2-docetaxel at 30 mg/kg docetaxel, by IV × 1 to nu/nu mice bearing intracranial 
A549 tumors. Concentrations below the lower limit of quantitation (LLOQ) are not shown. Pharmacokinetic analysis included 
(A) plasma; (B) contralateral brain; (C) peritumoral brain; and (D) intracranial tumors.
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studies. Two separate efficacy studies were performed 
and experiments combined, for n > 9/group. Tumor 
volume change and weight change figures were gener-
ated using GraphPad Prism 6, with groups normalized 
to a baseline value from initial tumor volumes or initial 
weights at grouping.
Pharmacokinetics analysis
After sacrifice, plasma, contralateral brain, intracra-
nial tumor and the peritumor brain tissue consisting 
of the 2 mm perimeter surrounding intracranial tumor 
were collected and snap frozen in liquid nitrogen. The 
associations between injected agents (SM-docetaxel, 
PRINT-docetaxel and PRINT-C2-docetaxel) and 
downstream pharmacokinetic analytes (docetaxel and 
C2-docetaxel) are summarized in Table 1. Docetaxel 
was measured in all samples after administration of 
SM-docetaxel, PRINT-docetaxel and PRINT-C2-
docetaxel, as previously described [13]. The analysis 
of docetaxel in PRINT-docetaxel samples measured 
nanoparticle-encapsulated + released docetaxel. The 
analysis of docetaxel from PRINT-C2-docetaxel 
samples measured converted C2-docetaxel, released 
from nanoparticle-encapsulation [13]. C2-docetaxel 
was measured in all samples after administration of 
PRINT-C2-docetaxel, representative of nanoparticle-
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encapsulated + released C2-docetaxel prodrug. All 
samples were analyzed using liquid chromatography 
tandem mass spectroscopy (LC-MS/MS), as  previously 
described [13].
Data analysis & statistical methods
Generally, all data analysis and statistical methods 
were performed as previously described [6,13,14,17].
Pharmacokinetic analysis
Pharmacokinetic data were analyzed by noncompart-
mental methods using WinNonLin Professional Edi-
tion version 6.1 (Pharsight Corp, NC, USA). The 
area under the concentration curve (AUC) versus 
time was calculated from 0 to t
last
. The conversion of 
PRINT-C2-docetaxel prodrug to active docetaxel was 
calculated from the PRINT-C2-docetaxel AUCs as 
follows: [AUC_doctaxel/(AUC_C2-docetaxel+AUC_
docetaxel)]*100 [13].
Efficacy
The Kaplan–Meier method and Log rank test were 
used to estimate and compare median survival between 
treatment groups. Median survivals, along with their 
95% confidence intervals, and Log-rank test p-values 
were reported.
Tumor volume changes & mouse weight change 
analysis
Both fold change in tumor volumes and mice weight 
over time were determined relative to treatment start 
date. Linear mixed models, with a random intercept 
and slope, were used to evaluate changes over time, 
overall and between groups. SAS statistical software, 
v9.3, was used for these analyses (NC, USA).
Results
Pharmacokinetics of SM-docetaxel, PRINT-
docetaxel & PRINT-C2-docetaxel in intracranial 
NSCLC tumor-bearing nude mice
To demonstrate that PRINT-docetaxel and PRINT-
C2-docetaxel formulations can increase intracranial 
tissue exposure to docetaxel, a pharmacokinetic study 
was performed using the A549 human non-small-cell 
lung cancer (NSCLC) brain metastases xenograft 
murine model with administration of SM-docetaxel, 
PRINT-docetaxel and PRINT-C2-docetaxel. This 
KRAS-activated NSCLC background was shown to 
be responsive to both PRINT-docetaxel formulations 
in a subcutaneous tumor model [13].
Table 1 summarizes the association of analytes 
(docetaxel or C2-docetaxel) with chemotherapeutic 
agents injected (SM-docetaxel, PRINT-docetaxel, 
PRINT-C2-docetaxel). Figure 1 shows the pharmaco-
kinetic profile of docetaxel after single dose administra-
tion of SM-docetaxel, PRINT-docetaxel, PRINT-C2-
docetaxel, in plasma, contralateral brain, peritumoral 
brain and intracranial tumor.
In each tissue analyzed, the nanoparticle formu-
lations achieved higher exposures of drug in tumors 
compared with SM-docetaxel. Both PRINT-docetaxel 
and PRINT-C2-docetaxel formulations, measured 
by docetaxel and C2-docetaxel respectively, were 
detected 24 h or later after administration in plasma 
and contralateral brain. Docetaxel from SM-docetaxel 
or converted C2-docetaxel prodrug were detectable for 
6 h after administration of SM-docetaxel or PRINT-
C2-docetaxel in plasma and undetectable 2 h after 
administration in contralateral brain. In peritumoral 
brain, docetaxel from PRINT-docetaxel was present 
at 24 h after administration, as compared with SM-
docetaxel, C2-docetaxel from PRINT-C2-docetaxel, 
or docetaxel from converted C2-docetaxel, all unde-
tected beyond 6 h after administration. Docetaxel 
from the converted C2- prodrug was detected in 
intracranial tumors for up to 24 h, as compared with 
SM-docetaxel, C2-docetaxel prodrug from PRINT-
C2-docetaxel, or docetaxel from PRINT-docetaxel, 
all undetectable after 6 h.
While AUCs were similar in contralateral brain, 
peritumoral brain and intracranial tumor, the Cmax 
for the docetaxel converted from PRINT-C2-docetaxel 
prodrug was three- to fourfold lower than SM-docetaxel 
in these intracranial tissues tested. These data are sum-
marized in Table 2. These data also show a greater 
than threefold increased conversion of the released 
C2-docetaxel prodrug in intracranial tumor (10.9%) 
as compared with plasma, contralateral brain or peri-
tumoral brain (3% or less). These data demonstrate 
that docetaxel from both PRINT-docetaxel formula-
tions cross the blood–brain barrier and  accumulate in 
 intracranial tumors.
Table 1. Pharmacokinetic analytes of injected agents.
Injected agent Docetaxel C2-docetaxel
SM-Docetaxel Free NA
PRINT-Docetaxel Encapsulated + free NA
PRINT-C2-Docetaxel Free converted Encapsulated + free 
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PRINT-C2-docetaxel increases survival as 
compared with docetaxel & PRINT-docetaxel in 
an intracranial model of NSCLC
The efficacy of PRINT-docetaxel formulations as 
compared with SM-docetaxel were evaluated in the 
NSCLC brain metastases model A549 (Figure 2). 
Analysis of tumor growth rates by bioluminescence is 
summarized in Figure 2A. The growth rate of vehicle-
control treated tumors was significantly higher from 
all treatment groups from start of treatment (day 21) 
through day 60 (p < 0.0001); there were no differences 
in tumor growth rate between all other treatment 
groups (p > 0.7).
Comparison of median survivals by treatment 
(Figure 2B) demonstrated that the PRINT-C2-docetaxel 
significantly improved survival by greater than 35% as 
compared with other treatment arms. Median survival 
in response to PRINT-C2-docetaxel was 90 days (95% 
CI: 70–103) as compared with vehicle control (61 days 
(95% CI: 50–68), SM-docetaxel (66.5 days (95% CI: 
57–86), and PRINT-docetaxel (58 days [95% CI: 
37–79], overall p-value: p = 0.1556). These data illus-
trate that while all treatments decreased tumor burden 
and slowed tumor growth rates, only treatment with 
the PRINT-C2-docetaxel prodrug improved survival.
Figure 3 demonstrates that mice treated with 
PRINT-C2-docetaxel therapy exhibited stable weight 
during the first 6 weeks of therapy. Mice in the other 
treatment or control groups exhibited weight loss dur-
ing the first 6 weeks of therapy, significantly different 
than that of PRINT-C2-docetaxel (p < 0.003). The 
weight loss in the PBS group followed closely with 
tumor burden as expected. However, in SM-docetaxel 
and PRINT-docetaxel groups, weight loss did not cor-
respond with tumor burden and steadily decreased 
with treatment number. This demonstrates that 
PRINT-C2-docetaxel was effective in reducing intra-
cranial tumor burden without significant toxicity dur-
ing the first 6 weeks of treatment resulting in improved 
overall survival.
Discussion
Brain metastases, increasing in frequency as thera-
peutics for advanced extracranial cancer progress and 
evolve, require novel therapeutic approaches. Therapies 
for brain metastases should effectively target tumor tis-
sue in the brain at concentrations high enough to induce 
tumor cell death and/or stabilize disease, while mini-
mizing normal intracranial and extracranial  toxicities, 
thereby increasing survival and quality of life.
This work shows that intravenous injections of 
PRINT PLGA nanoparticle formulations of docetaxel 
and the prodrug C2-docetaxel deliver docetaxel to 
intracranial tumors and exhibit antitumor activ-
ity against an orthotopic model of KRAS-NSCLC 
brain metastases. AUC analysis illustrates that deliv-
ery of released docetaxel from PRINT-docetaxel or 
the C2-docetaxel prodrug via PRINT-C2-docetaxel 
nanoparticles was higher than that of SM-docetaxel 
in intracranial tumors, 13-fold for PRINT-docetaxel 
and sevenfold for PRINT-C2-docetaxel (Table 2). 
Moreover, nanoparticles were detected in plasma for 
up to 72 h (Figure 1). In comparison to prior studies 
with PRINT-docetaxel formulations, the AUC of the 
intracranial tumor for each treatment were at lower 
levels than those described in the A549 tumor flank 
model (4885 vs 60,858 for PRINT-docetaxel; 2634 vs 
26,799 for PRINT-C2-docetaxel; 372 vs 73,222 for 
SM-docetaxel), although plasma AUCs for all treat-
ments were higher in this study as compared with the 
flank study (326,352 vs 79,192 for PRINT-docetaxel; 
360,281 vs 227,735 for PRINT-C2-docetaxel; 4742 vs 
1227 for SM-docetaxel) for similar dosing concentra-
tions [13]. As compared with flank studies [13], intra-
Table 2. Pharmacokinetic parameters.
Injected agent Taxotere PRINT-docetaxel PRINT-C2-dimethyl-Si-docetaxel Conversion 
of C2-
docetaxel to 
docetaxel
Analyte Docetaxel Docetaxel C2-docetaxel Docetaxel 
 AUC ng/
ml*h
Cmax ng/ml AUC ng/
ml*h
Cmax ng/ml AUC ng/
ml*h
Cmax ng/ml AUC ng/
ml*h
Cmax ng/ml  
Plasma 4742 10,256 326,352 147,694 360,281 125,535 7683 5475 2.1%
Contralateral 
brain
189 535 4274 1516 5892 1772 109 90 1.8%
Peri-tumoral 
brain
118 252 2546 1516 4011 1740 125 89 3.0%
Brain tumor 372 394 4885 8558 2634 1704 321 120 10.9% 
1952 Nanomedicine (Lond.) (2016) 11(15)
Figure 2. All docetaxel therapies decrease tumor burden, but PRINT-C2-docetaxel improves survival. (A) The 
tumor volume changes among treatment groups are similar to each other, but all are significantly better than 
the PBS control (p < 0.0001). (B) PRINT-C2-docetaxel improved median survival by greater than 35% over all other 
treatments and PBS.
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cranial tumor AUCs were an order of magnitude lower 
for each treatment observed, suggesting a drug delivery 
issue, likely related to the blood–brain barrier [12,20].
The silyl ether C2′ alcohol of docetaxel was gener-
ated to produce an acid labile docetaxel prodrug that 
could specifically target the acidic environments of 
cancer cells. The applicability of the acid labile chemis-
try of silyl ethers as anticancer prodrugs was previously 
demonstrated with gemcitabine [23]. In this case, lower 
pH increased both prodrug release and conversion from 
the PRINT nanoparticle. Consistent with the model, 
PRINT-C2-docetaxel had an increased conversion of 
10.9% in intracranial tumors, as compared with 2.1, 
1.8 and 3.0% in plasma, contralateral and peritumor 
environments, respectively. The C2-docetaxel conver-
sion rate in intracranial tumors is lower than in the 
flank model (32.5 vs 10.9%), but at a similar conver-
sion value as described for liver [13], and is within the 
range of other clinically relevant prodrug strategies. 
We did not determine a mechanism for the decrease in 
prodrug conversion in the intracranial tumors, which 
could include mass action effects due to lower concen-
trations of C2-docetaxel in intracranial versus extra-
cranial tumors or a difference in tumor biology based 
on the contributing brain tissue environment.
While all treatment arms decreased tumor burden 
and slowed intracranial growth rates by biolumines-
cence imaging, the PRINT-C2-docetaxel increased 
median survival, by greater than 35%, as compared 
with all other treatment arms. We hypothesize that the 
efficacy of the PRINT-C2-docetaxel is due to decreases 
in toxicity [13]. This is supported by the following evi-
dence: 1) Pharmacodynamics from previous studies 
show that PRINT-C2-docetaxel has slower release 
kinetics as compared with PRINT-docetaxel due to the 
increased lipophilicity of C2-docetaxel as compared 
with docetaxel; 50% of the PRINT-C2-docetaxel is 
released at 24 h as compared with less than 6 h with 
PRINT-docetaxel cargo. Additionally, C2-docetaxel 
has an 8 h half-life for conversion to docetaxel in 
PBS [13]. This demonstrates that the longer retention 
of C2-docetaxel in the nanoparticle, with an added 
conversion rate to docetaxel, delays active drug release, 
minimizing toxicity. 2) In this study, the docetaxel 
from the release and conversion of the PRINT encap-
sulated C2-docetaxel has a lower Cmax in plasma than 
the SM-docetaxel, although converted docetaxel from 
PRINT-C2-docetaxel was found 24 h after injection 
in contrast to SM-docetaxel or PRINT-docetaxel in 
intracranial tumor. This supports previous pharmaco-
dynamics analysis [13] and is consistent with the hypoth-
esis that PRINT-C2-docetaxel would be less toxic than 
SM-docetaxel in these studies. 3) While all docetaxel 
treatments decreased tumor burden (Figure 2A), only 
the PRINT-C2-docetaxel increased median survival as 
compared with all other treatment arms (Figure 2B). 
4) Docetaxel treatment is consistently associated with 
neutropenia, which may be minimized by PRINT-
C2-docetaxel. In previous studies [13], 4 days after the 
sixth intravenous dose of 20 mg/kg, animals treated 
with PRINT-C2-docetaxel had PBS control levels of 
white blood cells, and twice the white blood cell levels 
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Figure 3. PRINT-C2-Docetaxel minimizes docetaxel toxicity as measured by average weight change. Weight 
change is summarized for first 6 weeks of treatment. Weight change between groups was found to be statistically 
significant from each other (p < 0.0001), with PRINT-C2-docetaxel different statistically from SM-docetaxel and 
PRINT-docetaxel (p < 0.003).
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as SM-docetaxel treated animals, at equimolar dosing. 
5) With regards to median survival and the 60 days 
post-intracranial injection with six doses of treatment, 
the SM-docetaxel, PRINT-docetaxel and PBS control 
groups showed weight decline that correlated to time 
of death. However, tumor burden in SM-docetaxel and 
PRINT-docetaxel was significantly decreased as com-
pared with PBS controls, supporting treatment-specific 
toxicity. Mice treated with the PRINT-C2-docetaxel 
showed no change in weight during this timeframe 
and decreased tumor burden. This was also consistent 
with previous studies [13].
Targeting drug to tumors through nanoparticle 
delivery methodologies is a promising strategy to 
increase tumor cytotoxicity and decrease drug-asso-
ciated toxicities. Encapsulated cargo has a different 
pharmacodynamic profile than free drug and takes 
on the pharmacokinetics of its carrier. This results 
in increased systemic half-life of the drug, changes in 
the drug tissue distribution and increased drug-tumor 
exposure with less systemic toxicity [6,9,13,17]. In this 
manner, nanoparticle encapsulation generates a pro-
drug of the free drug cargo [6]. However, in this study, 
simply changing drug distribution and increasing 
target dosing by encapsulating free chemotherapeutic 
drug (i.e., docetaxel) did not balance decreased sys-
temic toxicity to support extended survival. The mech-
anism supporting decreased PRINT-C2-docetaxel 
toxicity may include the longer half-life of cargo release 
as compared with PRINT-docetaxel (24 h vs <6 h at 
pH 7.4), as well as the timing and specificity of the 
target tissue activation [13].
Target tissue activation of the C2-docetaxel prodrug 
is modeled to occur through ethyl-dimethyl-silyl-ether 
docetaxel protonation and hydrolysis, resulting in 
docetaxel release. This reaction proceeds in acidic envi-
ronments like tumors, without enzymatic activity [13]. 
Cancer cells’ dependency for anaerobic metabolism 
generates an acidic extracellular microenvironment 
and intracellular endocytic and lysosomal vesicular 
network. This increases activation of acid-labile mol-
ecules for anticancer therapy with some tumor speci-
ficity. This strategy is being vigorously tested in the 
context of acid labile nanoparticles, targeting agents 
and prodrugs like C2-docetaxel [21,22]. This study 
introduces the application of the acid labile chemistry 
of silyl ethers tagged chemotherapeutics as a targeting 
agent for intracranial tumors.
Conclusion
We conclude that PRINT nanoparticles of docetaxel 
can enter and inhibit growth of human intracranial 
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tumors in a murine xenograft model of NSCLC. We 
show that intravenous administrations of PRINT-C2-
docetaxel prodrug are more efficacious than either free 
docetaxel or PRINT-docetaxel against a brain metas-
tasis model of NSCLC. We conclude that PRINT-C2-
docetaxel increases survival by decreasing systemic tox-
icities, through slower chemotherapeutic release and the 
targeted conversion of the prodrug in the intracranial 
tumor environment. We confirm that decreasing the 
systemic toxicity of chemotherapeutics is an important 
adjunct treatment strategy against intracranial cancers.
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Executive summary
Background
•	 Nanoparticle formulations of PRINT-docetaxel and PRINT acid labile C2-docetaxel prodrug have been shown to 
be more effective than free drug against the A549 NSCLC subcutaneous xenograft model.
Results
•	 Given at similar molar doses, docetaxel and C2-prodrug docetaxel from PRINT-nanoparticle formulations 
were found in intracranial tumor and brain tissues at greater than sevenfold higher concentrations than 
SM-docetaxel at all time points.
•	 The AUCs for docetaxel from converted C2 prodrug and SM-docetaxel were similar in intracranial tissues 
tested; the Cmax for C2 prodrug was three- to fourfold lower than SM- docetaxel.
•	 Conversion of the acid-labile C2 prodrug to docetaxel was highest in intracranial tumor tissue, 10.9% as 
compared with 2.1% in plasma, 1.8% in contralateral brain and 3.0% in peritumoral brain.
•	 All docetaxel treatments significantly decreased tumor burden as compared with control during the first 6 
weeks of treatment (p < 0.0001).
•	 The PRINT C2-docetaxel prodrug formulation treatment increased median survival to 90 days, as compared 
with 61 days for control, 58.5 days with PRINT-docetaxel and 66.5 days with SM-docetaxel.
•	 PRINT C2-docetacel was less toxic by measures of weight change during the first 6 weeks of treatment.
Discussion
•	 Acid-labile PRINT C2-prodrug nanoparticle, because of improved tumor specificity resulting in decreased 
systemic toxicity, had a superior efficacy as compared with SM-docetaxel and PRINT-docetaxel against a NSCLC 
brain metastases model.
•	 The combination of PRINT PLGA nanoparticle technology with a tumor activated agent may be a useful 
anticancer therapeutic for intracranial tumors.
www.futuremedicine.com 1955future science group
Efficacy & PK of docetaxel-PRINT® nanoparticle formulation against NSLC brain metastases    Research Article
References
Papers of special note have been highlighted as: • of interest; 
•• of considerable interest
1 Yamanaka R. Medical management of brain metastases from 
lung cancer (Review). Oncol. Rep. 22(6), 1269–1276 (2009).
2 Reck M, Heigener DF, Mok T, Soria J-C, Rabe KF. 
Management of non-small-cell lung cancer: recent 
developments. Lancet 382(9893), 709–719 (2013).
3 National Cancer Institute. SEER Stat Fact Sheets: Lung and 
Bronchus Cancer.  
http://seer.cancer.gov/statfacts/html/lungb.html
4 Schuchert MJ, Luketich JD. Solitary sites of metastatic 
disease in non-small cell lung cancer. Curr. Treat. Options 
Oncol. 4(1), 65–79 (2003).
5 Lwin Z, Riess JW, Gandara D. The continuing role of 
chemotherapy for advanced non-small cell lung cancer in the 
targeted therapy era. J. Thorac. Dis. 5(Suppl. 5), S556–S564 
(2013).
6 Anders CK, Adamo B, Karginova O et al. Pharmacokinetics 
and efficacy of PEGylated liposomal doxorubicin in an 
intracranial model of breast cancer. PLoS ONE 8(5), e61359 
(2013).
•	 Demonstration	of	the	efficacy	of	nanoparticles	loaded	with	
chemotherapeutics	against	preclinical	intracranial	models	
of	triple	negative	breast	cancer.
7 Zamboni WC, Strychor S, Joseph E et al. Plasma, tumor, 
and tissue disposition of STEALTH liposomal CKD-602 
(S-CKD602) and nonliposomal CKD-602 in mice bearing 
A375 human melanoma xenografts. Clin. Cancer Res. 13(23), 
7217–7223 (2007).
8 Walsh MD, Hanna SK, Sen J et al. Pharmacokinetics 
and antitumor efficacy of XMT-1001, a novel, polymeric 
topoisomerase I inhibitor, in mice bearing HT-29 human 
colon carcinoma xenografts. Clin. Cancer Res. 18(9), 
2591–2602 (2012).
9 Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated 
in sterically stabilized liposomes for the treatment of a brain 
tumor model: biodistribution and therapeutic efficacy. 
J. Neurosurg. 83(6), 1029–1037 (1995).
10 Koukourakis MI, Koukouraki S, Fezoulidis I et al. High 
intratumoural accumulation of stealth liposomal doxorubicin 
(Caelyx) in glioblastomas and in metastatic brain tumours. 
Br. J. Cancer 83(10), 1281–1286 (2000).
11 Linot B, Campone M, Augereau P et al. Use of liposomal 
doxorubicin-cyclophosphamide combination in breast cancer 
patients with brain metastases: a monocentric retrospective 
study. J. Neurooncol. 117(2), 253–259 (2014).
12 Lockman PR, Mittapalli RK, Taskar KS et al. Heterogeneous 
blood-tumor barrier permeability determines drug efficacy in 
experimental brain metastases of breast cancer. Clin. Cancer 
Res. 16(23), 5664–5678 (2010).
•	 Demonstrates	that	intracranial	tumors	can	have	a	
compromised	blood–brain	barrier	that	allows	increased	
chemotherapeutic	penetrance	as	compared	with	brain,	but	
less	than	extracranial	tissues.
13 Chu KS, Finniss MC, Schorzman AN et al. Particle 
replication in nonwetting templates nanoparticles with 
tumor selective alkyl silyl ether docetaxel prodrug reduces 
toxicity. Nano Lett. 14(3), 1472–1476 (2014).
••	 Demonstrates	the	efficacy	of	the	PRINT-C2-Docetaxel	
prodrug	against	an	extracranial	model	of	A549.
14 Karginova O, Siegel MB, Van Swearingen AED et al. 
Efficacy of carboplatin alone and in combination with 
ABT888 in intracranial murine models of BRCA-mutated 
and BRCA-wild-type triple-negative breast cancer. Mol. 
Cancer Ther. 14(4), 920–930 (2015).
15 Perry JL, Herlihy KP, Napier ME, DeSimone JM. PRINT: 
a novel platform toward shape and size specific nanoparticle 
theranostics. Acc.Chem. Res. 44(10), 990–998 (2011).
16 Gratton SEA, Ropp PA, Pohlhaus PD et al. The effect of 
particle design on cellular internalization pathways. Proc. 
Natl Acad. Sci. USA 105(33), 11613–11618 (2008).
17 Chu KS, Hasan W, Rawal S et al. Plasma, tumor and tissue 
pharmacokinetics of Docetaxel delivered via nanoparticles 
of different sizes and shapes in mice bearing SKOV-3 human 
ovarian carcinoma xenograft. Nanomedicine 9(5), 686–693 
(2013).
•	 Demonstrates	the	enhanced	half-life	and	decreased	
clearance	of	the	PRINT	particle	320	×	80	nm	used	in	this	
study.
18 Enlow EM, Luft JC, Napier ME, DeSimone JM. Potent 
engineered PLGA nanoparticles by virtue of exceptionally 
high chemotherapeutic loadings. Nano Lett. 11(2), 808–813 
(2011).
19 Owonikoko TK, Arbiser J, Zelnak A et al. Current 
approaches to the treatment of metastatic brain tumours. 
Nat. Rev. Clin. Oncol. 11(4), 203–222 (2014).
20 Connell JJ, Chatain G, Cornelissen B et al. Selective 
permeabilization of the blood–brain barrier at sites of 
metastasis. J. Natl Cancer Inst. 105(21), 1634–1643 (2013).
21 Liu J, Huang Y, Kumar A et al. pH-sensitive nano-systems 
for drug delivery in cancer therapy. Biotechnol. Adv. 32(4), 
693–710 (2014).
22 Du J, Lane LA, Nie S. Stimuli-responsive nanoparticles for 
targeting the tumor microenvironment. J. Control. Release 
219, 205–214 (2015).
•	 Review	of	the	use	of	the	tumor	microenvironment,	
including	decreased	pH	and	hypoxia,	for	anticancer	
therapy.
23 Parrott MC, Finniss M, Luft JC et al. Incorporation and 
controlled release of silyl ether prodrugs from PRINT 
nanoparticles. J. Am. Chem. Soc. 134(18), 7978–7982 
(2012).
••	 Demonstrates	the	ability	to	create	an	acid	labile	
chemotherapeutic	prodrug	using	silyl	ether	chemistry,	
effective	with	PRINT	nanotechnology.
